Responders associated with baseline blast percentage in the blood and bone marrow. Responders to the treatment were associated with a statistically significant lower absolute blast counts (<25%) at baseline in both the (A) blood and (B) bone marrow compared with that of nonresponders. For bone marrow, n = 111 and for peripheral blood, n = 104.